富瀚微(300613.SZ)正籌劃發行股份及支付現金購買眸芯科技49%股權 明日停牌
格隆匯5月3日丨富瀚微(300613.SZ)公佈,公司正在籌劃發行股份及支付現金購買資產並募集配套資金暨關聯交易事項,因有關事項尚存在不確定性,為了維護投資者利益,避免對公司證券造成重大影響,根據深圳證券交易所的相關規定,經公司申請,公司股票及債券自2023年5月4日開市起停牌。
本次交易標的資產為眸芯科技(上海)有限公司(以下簡稱“眸芯科技”)49%股權。本次交易前公司持有眸芯科技51%股權,眸芯科技為公司控股子公司,本次交易後眸芯科技將成為公司全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.